CLYM on Nasdaq

Climb Bio, Inc.

American pharmaceutical preparations company based in Wellesley Hills.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

  • TickerCLYM on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersDE
  • Incorporated inDE2
  • Business address20 William Street, Suite G50, Wellesley Hills, Ma2
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34567-$67.9M in 2025+224% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$20.9M-$20.9M20202021: -$35.7M-$35.7M2021+70%2022: -$45.1M-$45.1M2022+27%2023: -$40.3M-$40.3M2023−11%2024: -$82.0M-$82.0M2024+104%2025: -$67.9M-$67.9M2025−17%
Net income34567-$59.9M in 2025+190% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$20.7M-$20.7M20202021: -$47.5M-$47.5M2021+130%2022: -$45.2M-$45.2M2022−5%2023: -$35.1M-$35.1M2023−22%2024: -$73.9M-$73.9M2024+110%2025: -$59.9M-$59.9M2025−19%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Acquired in-process research and development, related party$0$51.7M
Research and development expense$46.7M$14.3M
General and administrative$21.2M$16.0M
Total operating expenses$67.9M$82.0M
Total loss from operations-$67.9M-$82.0M
Foreign currency loss-$291.0K-$9.0K
Interest income$8.3M$8.1M
Total other income (expense)$8.0M$8.1M
Net loss per share, diluted-$0.88-$1.53
Net loss per share, basic-$0.88-$1.53
Weighted-average number of shares used to compute net loss per share, diluted67.8M shares48.2M shares
Weighted-average number of shares used to compute net loss per share, basic67.8M shares48.2M shares
Net Income (Loss)-$59.9M-$73.9M
Unrealized gain on marketable securities$412.0K$25.0K
Comprehensive loss-$59.4M-$73.9M
Income tax$0$0

Compare Climb Bio, Inc. with another company

Leadership

Who has led Climb Bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert Azelby2021–2022
  2. Aoife Brennan2024–now

Chair

  1. Andrew David Levin2023–2024

President

  1. Robert Azelby2022
  2. Aoife Brennan2024–now

Chief financial officer

  1. Erin Lavelle2021–2022
  2. Susan Altschuller2025–now

Chief operating officer

  1. Erin Lavelle2021–2022
  2. Brett Kaplan2024–2025
2025
Board members and other officers (19)

Former names

  • Eliem Therapeutics, Inc.Feb 19, 2019 to Sep 20, 20242

Timeline

  1. Jun 27, 2024New chief executive Aoife Brennan becomes CEO10
  2. Aug 9, 2021New chief executive Robert Azelby becomes CEO11

Filings

260 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 60 major events, 100 insider forms, 32 large holders, 3 private raises, 44 other. The latest 20:

  1. Sep 30, 20264 EDGAR
  2. Sep 17, 20264 EDGAR
  3. Sep 15, 2026144 EDGAR
  4. Sep 3, 20268-K EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 14, 20268-K EDGAR
  7. Aug 6, 202610-Q EDGAR
  8. Aug 6, 20268-K EDGAR
  9. Jul 8, 2026SCHEDULE 13G EDGAR
  10. Jul 7, 2026SCHEDULE 13D/A EDGAR
  11. Jul 1, 20264 EDGAR
  12. Jul 1, 20264 EDGAR
  13. Jul 1, 20263 EDGAR
  14. Jul 1, 20268-K EDGAR
  15. Jun 30, 20264 EDGAR
  16. Jun 30, 2026144 EDGAR
  17. Jun 12, 20268-K EDGAR
  18. Jun 12, 2026424B5 EDGAR
  19. Jun 11, 20268-K EDGAR
  20. Jun 9, 2026EFFECT EDGAR

The 260 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 32 such filings since October 2021, the latest 10:

  1. Aug 14, 2026SCHEDULE 13G/A
  2. Jul 8, 2026SCHEDULE 13G
  3. Jul 7, 2026SCHEDULE 13D/A
  4. Apr 29, 2026SCHEDULE 13D/A
  5. Feb 17, 2026SCHEDULE 13G
  6. Dec 15, 2025SCHEDULE 13D/A
  7. Oct 16, 2025SCHEDULE 13D/A
  8. Oct 7, 2025SCHEDULE 13D/A
  9. Sep 18, 2025SCHEDULE 13G
  10. Feb 13, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 29, 2026Raised $110.1 million in a private offering of equity Form D: 22 investors so far Form D
  2. Jun 27, 2024Raised $41.9 million in a private offering of equity Form D: 6 investors so far Form D
  3. Jun 27, 2024Raised $120 million in a private offering of equity Form D: 8 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.11,300,939$147.4M1.3%No change
Fmr LLC6,790,364$88.5M0.0%+6,783,967
UBS Group AG3,404,866$44.4M0.0%+3,318,921
Braidwell LP2,797,375$36.5M1.4%+1,267,700
Adage Capital Partners Gp, L.l.c.2,506,000$32.7M0.0%New
BlackRock, Inc.2,354,872$30.7M0.0%+1,953,223
Cormorant Asset Management, LP2,106,000$27.5M1.4%New
Frontier Capital Management Co LLC1,939,019$25.3M0.2%New
Vanguard Capital Management LLC1,698,654$22.2M0.0%+519,995
Woodline Partners LP1,582,291$20.6M0.1%New
Citadel Advisors LLC1,297,972$16.9M0.0%+952,309
Redmile Group, LLC1,226,330$16.0M1.1%New
Great Point Partners LLC1,000,000$13.0M3.1%−334,130
Affinity Asset Advisors, LLC972,000$12.7M0.6%+272,000
Millennium Management LLC908,198$11.8M0.0%−368,062
ADAR1 Capital Management, LLC822,649$10.7M0.5%+224,987
Driehaus Capital Management LLC790,000$10.3M0.1%+189,054
Geode Capital Management, LLC782,199$10.2M0.0%+469,200
Stempoint Capital LP742,745$9.7M1.7%New
State Street Corp686,772$9.0M0.0%+554,772
Ameriprise Financial Inc657,971$8.6M0.0%New
Parkman Healthcare Partners LLC563,484$7.3M0.8%New
Superstring Capital Management LP521,082$6.8M4.3%+321,873
Sphera Funds Management Ltd.483,747$6.3M0.9%+64,500
Invesco Ltd.373,445$4.9M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32